Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:annualVisitors |
millions
|
| gptkbp:clinicalTrials |
conducted
|
| gptkbp:developedBy |
Albert_Sabin
|
| gptkbp:evaluates |
high
|
| gptkbp:firstHeld |
gptkb:the_United_States
|
| gptkbp:has |
one or two doses
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sabin vaccine
|
| gptkbp:introduced |
1961
|
| gptkbp:isRecognizedFor |
immunocompromised individuals
|
| gptkbp:livePerformance |
true
|
| gptkbp:localEconomy |
significant reduction in polio cases
|
| gptkbp:notable_player |
over 90%
live attenuated |
| gptkbp:oversees |
recommended for children
|
| gptkbp:patentStatus |
expired
|
| gptkbp:producedBy |
various pharmaceutical companies
|
| gptkbp:replacedBy |
inactivated polio vaccine in some countries
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
generally safe
|
| gptkbp:sideEffect |
mild
|
| gptkbp:storage |
2 to 8 °C
|
| gptkbp:targets |
polio
|
| gptkbp:team |
yes
|
| gptkbp:type |
oral vaccine
|
| gptkbp:usedIn |
mass immunization campaigns
|
| gptkbp:wasAffecting |
long-term
|